Jason Kropp

Jason Kropp is the current Director of Pharmaceutical Development at Nuvalent. Jason has over 20 years of experience in the pharmaceutical industry, specializing in CMC operations and project management. Jason has held previous positions as the Director of CMC Operations at Decibel Therapeutics, Associate Director of CMC Operations at Constellation Pharmaceuticals, and Manager of CMC Operations at Infinity Pharmaceuticals. Jason has been instrumental in the development and commercialization of several drugs, including duvelisib (IPI-145), a potent PI3K-δ,γ inhibitor for the treatment of hematologic malignancies, and retaspimycin hydrochloride (IPI-504), an Hsp90 inhibitor in phase 2 clinical trials in multiple oncology indications. Jason has a Bachelor of Science in Chemistry from the University of Massachusetts Amherst and a Master of Science in Organic Chemistry from Northeastern University.

Jason Kropp attended Worcester Polytechnic Institute from 2001 to 2005, where they earned a Bachelor of Science in Chemistry.